Projekte (gegliedert nach Institutionen)
![]() | Eine Stufe nach oben |
Hegner, Philipp
, Baier, Maria J.
, Krammer, Thomas, Seitz, Simon, Käs, Anna-Katharina, Zschiedrich, Tilman, Lukas, David, Lutz, Vanessa, Wolf, Matthias, Sinha, Frederick, Schopka, Simon
, Schmid, Christof, Kozakov, Kostiantyn
, Provaznik, Zdenek
, Maier, Lars S.
, Mustroph, Julian
und Wagner, Stefan
(2026)
Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction.
Cardiovascular Research 122 (6), S. 675-677.
Hegner, Philipp
, Drzymalski, Marzena, Biedermann, Alexander, Memmel, Bernadette, Durczok, Melanie, Wester, Michael
, Floerchinger, Bernhard, Provaznik, Zdenek
, Schmid, Christof, Zausig, York, Maier, Lars S.
und Wagner, Stefan
(2022)
SAR296968, a Novel Selective Na+/Ca2+ Exchanger Inhibitor, Improves Ca2+ Handling and Contractile Function in Human Atrial Cardiomyocytes.
Biomedicines 10 (8), S. 1932.
Arzt, Michael, Drzymalski, Marzena A., Ripfel, Sarah, Meindl, Sebastian, Biedermann, Alexander, Durczok, Melanie, Keller, Karoline, Mustroph, Julian, Katz, Sylvia, Tafelmeier, Maria, Lebek, Simon
, Flörchinger, Bernhard, Camboni, Daniele, Wittmann, Sigrid, Backs, Johannes, Schmid, Christof, Maier, Lars S.
und Wagner, Stefan
(2022)
Enhanced Cardiac CaMKII Oxidation and CaMKII-Dependent SR Ca Leak in Patients with Sleep-Disordered Breathing.
Antioxidants 11 (2), S. 331.
Lebek, Simon, Tafelmeier, Maria, Messmann, Rebecca, Provaznik, Zdenek, Schmid, Christof, Maier, Lars S., Birner, Christoph, Arzt, Michael und Wagner, Stefan
(2020)
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
European Journal of Heart Failure 22, S. 2248-2257.
Trum, Maximilian
, Riechel, Johannes, Lebek, Simon, Pabel, Steffen, Sossalla, Samuel T., Hirt, Stephan, Arzt, Michael, Maier, Lars S. und Wagner, Stefan
(2020)
Empagliflozin inhibits Na + /H + exchanger activity in human atrial cardiomyocytes.
ESC Heart Failure 2020, S. 1-9.
